ChemicalBook > Product Catalog >API >Drugs Influencing Immune Function >Immunomodulators >Tremelimumab

Tremelimumab

Request For Quotation
Tremelimumab Suppliers list
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  Gold
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Company Name: Wuhan Sunrise Technology Development Co., Ltd.  
Tel: 27-027-83314682 13554138826
Email: whsrtech@vip.163.com
Company Name: Beijing HuaMeiHuLiBiological Chemical   
Tel: 010-56205725
Email: waley188@sohu.com
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com

Tremelimumab manufacturers

  • Tremelimumab
  • Tremelimumab pictures
  • $155.00
  • 2026-08-15
  • CAS:745013-59-6
  • Purity: 95.00%
  • Supply Ability: 10g
Tremelimumab Basic information
Product Name:Tremelimumab
Synonyms:ticilimumab tremelimumab;Ticilimumab;Tremelimumab;Research Grade Tremelimumab (DHD17203);Research Grade Ticilimumab (DHD17204);Tremelimumab (anti-CTLA-4);Ticilimumab|||CP-675206
CAS:745013-59-6
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Tremelimumab Structure
Tremelimumab Chemical Properties
storage temp. Store at -20°C
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Tremelimumab Usage And Synthesis
UsesTremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research[1].
References[1] Comin-Anduix B, et al. Tremelimumab: research and clinical development. Onco Targets Ther. 2016 Mar 23;9:1767-76. DOI:10.2147/OTT.S65802
Tremelimumab Preparation Products And Raw materials
Tag:Tremelimumab(745013-59-6) Related Product Information
Follicle stimulating hormone Secukinumab Daratumumab Omalizumab Dulaglutide Trastuzumab emtansine palivizumab Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Eculizumab Ranibizumab Cetuximab Adalimumab Trastuzumab Rituximab Bevacizumab Nivolumab Lipopolysaccharides belimumab